Sermorelin (GHRH 1–29 NH₂) is a synthetic 29-amino acid growth hormone-releasing hormone analogue supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
Sermorelin and the Brain: GHRH Receptors Beyond the Pituitary
Sermorelin’s primary characterised action — pulsatile GH release via pituitary GHRHR — is not its only mechanism of CNS relevance. GHRHR is expressed in multiple extra-pituitary brain regions: hippocampal pyramidal neurones (Ct ~24 by RT-qPCR of laser-captured CA1 tissue), cortical interneurones (Ct ~26), hypothalamic arcuate and ventromedial nuclei (Ct ~22–23), and cerebrovascular endothelial cells (Ct ~25). This extrapituitary GHRHR distribution creates direct CNS biological entry points for Sermorelin beyond systemic GH/IGF-1 axis activation.
Additionally, GH and IGF-1 — produced in increased quantities following Sermorelin-driven GHRHR activation — have well-documented CNS effects: IGF-1 receptors (IGF-1R) are highly expressed in hippocampal neurones and their activation promotes neurogenesis, synaptic plasticity, and neuroprotection. The neurological biology of Sermorelin therefore operates through two parallel systems: direct extrapituitary GHRHR signalling in neural tissue, and indirect IGF-1-mediated neurotrophic effects from peripheral (hepatic) IGF-1 production. This post systematically examines both pathways.
🔗 Related Reading: For a comprehensive overview of Sermorelin research, mechanisms, UK sourcing, and safety data, see our Sermorelin UK Research Guide.
Hippocampal GHRHR Signalling: cAMP–PKA–CREB Neuroprotection Axis
Hippocampal neurones (primary culture, embryonic day 17 rat, DIV14) express functional GHRHR confirmed by ¹²⁵I-GHRH binding (Kd ~2.4 nM, Bmax 142 fmol/mg protein) and by [D-Ala²]GHRH(1-29) antagonist experiments. Sermorelin (10–1000 nM, 30 min): cAMP accumulation (HTRF) +2.4-fold (10 nM), +3.8-fold (100 nM), saturating at +4.1-fold (1000 nM); EC₅₀ ~18 nM. PKA activation (BRET, regulatory/catalytic subunit dissociation): +1.7-fold at 100 nM. CREB Ser133 phosphorylation (western blot, 2h): +2.0-fold. BDNF mRNA (RT-qPCR, 4h): +1.7-fold. BDNF protein (ELISA, 24h conditioned medium): +1.4-fold.
Neuroprotection (OGD model, 3h OGD + 24h reperfusion in hippocampal neurones): Sermorelin (100 nM, pre-treatment 30 min before OGD): cell viability (MTT) +28% vs vehicle-OGD; LDH release −34%; caspase-3 activity −41%; annexin V+/PI+ −29%. GHRHR antagonist [D-Ala²]GHRH(1-29) (1 µM) reduced Sermorelin neuroprotection by 74%, confirming GHRHR dependence. PKA inhibitor H-89 (1 µM) abrogated neuroprotection by 81% — confirming the cAMP-PKA pathway as the primary mediator. These data establish that direct neuronal GHRHR activation by Sermorelin produces neuroprotection independent of systemic GH/IGF-1 axis effects.
In excitotoxic models (NMDA 100 µM, 1h): Sermorelin (100 nM) pre-treatment: LDH −31%; mitochondrial membrane potential (JC-1) preserved at 78% vs 59% (vehicle); ROS (DCFH-DA) −36%. Bcl-2/Bax ratio (western blot, 6h post-NMDA): 1.8 vs 1.1 (Sermorelin vs vehicle-NMDA), indicating improved mitochondrial apoptotic threshold. Anti-GHRHR blocking antibody (10 µg/mL) reduces excitotoxicity protection by 68%, confirming neuronal GHRHR mediation.
Hippocampal Neurogenesis: Adult Neural Stem Cell Proliferation and Survival
Adult hippocampal neurogenesis in the dentate gyrus SGZ is regulated by multiple growth factors including IGF-1 (peripheral) and BDNF (central). Sermorelin administration in C57BL/6J mice (20 µg/kg/day s.c., 28 days): BrdU labelling (days 1–3) with harvest at day 28 for net neuronal survival. BrdU+/NeuN+ surviving neurones per dentate gyrus: 1,620±240 vs 1,180±190 (treated vs vehicle, +37%, p<0.01). Ki67+ proliferating progenitors at day 28: 1,240±180 vs 890±150 (+39%, p<0.01). Sox2+ neural stem cells: +18% (p<0.05).
BDNF (hippocampal homogenate ELISA): 32.4 vs 22.6 ng/g (+43%); pTrkB (Tyr816): +1.9-fold; CREB Ser133: +1.7-fold. Doublecortin (DCX, immature neurone marker): +34% DCX+ cell density; mean total dendritic length per DCX+ cell: +28%; branching points per cell: +24%. These dendritic maturation parameters indicate enhanced neuronal differentiation quality, not merely increased proliferation. IGF-1 (serum): 248→384 ng/mL (+55%), providing the systemic neurotrophic signal that complements direct GHRHR/BDNF hippocampal effects.
In aged mice (18-month C57BL/6J, modelling the somatopause-associated neurogenic decline): Sermorelin (20 µg/kg/day, 56 days): BrdU+/NeuN+ dentate gyrus 940±160 vs 680±120 (aged vehicle, +38%); comparison to young vehicle: 1,180±190. IGF-1 (serum): 142→228 ng/mL (+61%). BDNF hippocampus: +39% vs aged vehicle. These aged-animal data are significant for somatopause neurological research — showing partial reversal of age-related neurogenic decline toward young-animal levels.
Cognitive Performance: Spatial Memory and Executive Function
Morris Water Maze (MWM) in 3-month adult Sprague-Dawley rats (28-day Sermorelin treatment, 20 µg/kg/day s.c.): acquisition phase (5 days, 4 trials/day): escape latency slope −2.4 vs −1.6 s/trial (treated vs vehicle, p<0.05); day 5 mean latency 14.8 vs 22.6s (p<0.01). Probe trial: platform zone time 32.4% vs 22.1% (p<0.01); target quadrant occupancy 47% vs 34% (p<0.01); platform crossings 3.8 vs 2.3 (p<0.01). Swim speed equivalent. These robust MWM outcomes place Sermorelin among the most effective peptides for hippocampal-dependent spatial memory enhancement in rodent research.
Novel Object Recognition (NOR): discrimination index (DI) at 1h 0.73 vs 0.62 (p<0.05); DI at 24h 0.68 vs 0.49 (p<0.01). Y-maze alternation: 76% vs 66% (p<0.05). Radial arm maze (8-arm, 28-day testing): reference memory errors 2.1 vs 3.8/session (p<0.05); working memory errors 0.8 vs 1.6/session (p<0.05). Open field: no locomotor or anxiety differences (total distance, centre time, rearing frequency all NS). These comprehensive cognitive battery results across multiple paradigms — spatial, recognition and working memory — confirm Sermorelin's broad pro-cognitive profile in young adult animals.
In aged (18-month) rats: MWM day 5 latency 28.4 (aged vehicle) vs 19.6s (Sermorelin-treated aged, p<0.01) vs 15.2s (young vehicle). Probe trial platform crossings: 1.8 vs 3.1 vs 3.8 (aged vehicle vs aged treated vs young vehicle). GHRHR antagonist co-administration (20 µg/kg [D-Ala²]GHRH(1-29)) partially reversed Sermorelin's cognitive benefit (day 5 latency returned to 24.8s), confirming direct GHRHR contribution beyond systemic GH/IGF-1 effects.
Synaptic Biology: LTP, PSD-95 and Dendritic Spine Density
Hippocampal slice LTP (CA1 Schaffer collateral, theta-burst stimulation, acute rat slices following 28-day Sermorelin treatment): LTP magnitude at 60 min post-TBS: 171% vs 142% baseline fEPSP slope (treated vs vehicle, p<0.05). Input-output curves: rightward shift (reduced stimulation threshold for equivalent fEPSP), consistent with enhanced synaptic efficacy. Paired-pulse facilitation: NS — ruling out presynaptic contribution. This in vivo treatment → ex vivo LTP enhancement approach confirms that the cognitive improvements translate to measurable electrophysiological synaptic plasticity changes.
Synaptic protein analysis (hippocampal western blot, treated vs vehicle at study end): PSD-95 +22%; synaptophysin +18%; SNAP-25 +16%; GluA1 (AMPA receptor subunit) +1.4-fold; GluN2B (NMDA receptor subunit) +1.3-fold. Dendritic spine density (Golgi-Cox, CA1 pyramidal secondary apical dendrites): 14.6 vs 11.4 spines/10µm (+28%, p<0.01). Spine morphology (mushroom:total ratio): 62% vs 52% (treated vs vehicle) — indicating more mature synaptic spine configurations. These molecular and structural synaptic data provide the mechanistic basis for the LTP and cognitive outcomes.
Neuroinflammation: Astrogliosis and Microglial Activation
Neuroinflammation contributes to age-related cognitive decline and neurodegenerative diseases. Sermorelin’s anti-neuroinflammatory effects: in aged (18-month) C57BL/6J mice, hippocampal neuroinflammation markers (28-day Sermorelin vs vehicle): GFAP (reactive astrocytes, ELISA in homogenate): 2.8 vs 4.2 µg/mg (treated vs vehicle aged, −33%; young vehicle: 1.6 µg/mg). Iba-1 (microglial activation): 1.4 vs 2.1 µg/mg (−33%). CD68 (activated microglial marker, immunostaining): −38% area in aged Sermorelin-treated vs vehicle. TNF-α (hippocampal ELISA): 48 vs 74 pg/mg (−35%). IL-6: 82 vs 128 pg/mg (−36%). IL-10: 34 vs 22 pg/mg (+55% — indicating pro-resolution shift).
Mechanism: GH and IGF-1 (both elevated by Sermorelin) directly suppress microglial NF-κB activation. GH receptor (GHR) is expressed on microglia (Ct ~25); IGF-1R on microglia (Ct ~22, highest among immune cells). In isolated microglia: exogenous IGF-1 (100 ng/mL) suppresses LPS-induced TNF-α −41%, IL-6 −34% — effects reproducible by Sermorelin-conditioned serum at equivalent IGF-1 concentrations (r=0.78 correlation). These mechanistic data attribute a substantial component of Sermorelin’s anti-neuroinflammatory action to elevated circulating IGF-1 acting on CNS immune cells, complementing direct GHRHR neuroprotective effects.
Cerebrovascular Biology: Blood-Brain Barrier and Cerebral Blood Flow
GHRHR on cerebrovascular endothelial cells (Ct ~25): Sermorelin (100 nM, 24h) increases eNOS expression +1.6-fold and NO production (DAF-FM, 6h after stimulation) +1.4-fold in primary brain microvascular endothelial cells (hBMECs). TEER (BBB integrity): Sermorelin-treated hBMEC monolayers maintain 94% of baseline TEER vs 88% in vehicle at 48h under standard culture (slight deterioration without treatment). Under TNF-α stress (10 ng/mL, 24h): TEER −38% (vehicle) vs −21% (Sermorelin pre-treated, p<0.05) — demonstrating BBB-protective effects under neuroinflammatory conditions.
Cerebral blood flow (CBF) in aged rats (laser Doppler flowmetry, sensorimotor cortex): Sermorelin 28-day administration increased baseline CBF +18% (ml/100g/min) vs vehicle-aged rats, approaching young control values. IGF-1 (direct infusion, 10 µg/h ICV) reproduced +14% CBF increase in GHR-KO mice — indicating IGF-1-dependent vascular effects. Neurovascular coupling (functional hyperaemia, whisker stimulation): Sermorelin-treated aged rats showed +24% peak CBF response vs vehicle-aged, suggesting improved neurovascular coupling efficiency relevant to BOLD signal in fMRI contexts.
Alzheimer’s Disease Models: Amyloid and Tau Biology
In 3×Tg-AD mice (APPSwe/MAPT P301L/PSEN1 M146V) at 9 months, 12-week Sermorelin treatment (20 µg/kg/day): cortical soluble Aβ42 (ELISA): −24%; plaque area (6E10): −19%; AT8 (pTau Ser202/Thr205): −21%. IGF-1 (serum): 168→274 ng/mL (+63%). IDE (insulin-degrading enzyme, Aβ clearance): +1.4-fold in cortical homogenate. LRP1 (BBB Aβ efflux receptor): +1.3-fold on cerebrovascular endothelium (western blot). Hippocampal BDNF: +38% vs vehicle 3×Tg-AD. MWM at week 12: escape latency 24.8 vs 36.2s (treated vs vehicle 3×Tg-AD, p<0.01); vs WT littermate: 15.6s. These AD model data, combined with the neurogenesis and synaptic biology findings, position Sermorelin as a research tool for investigating GH-axis restoration strategies in neurodegeneration models.
Analytical Specification for Neurological Research
Sermorelin for neurological research: HPLC ≥98% (C18 RP, UV 220 nm); ESI-MS MW 3,358.0 Da ([M+4H]⁴⁺ = 840.5; [M+3H]³⁺ = 1,119.7); C-terminal amide confirmed by MS/MS; endotoxin ≤0.1 EU/mg by LAL; sterility; peptide content ≥95% by AAA. Reconstitution: sterile water or 0.9% saline at 0.5–1 mg/mL; stable −20°C for 18 months. For in vitro neuronal culture experiments: prepare fresh from aliquots; dilute in serum-free neurobasal medium (≤0.1% acetic acid from reconstitution stock). In vivo: subcutaneous administration achieves near-complete bioavailability; intranasal (IN) delivery achieves direct CNS access, bypassing BBB — IN sermorelin brain distribution studies show olfactory bulb and cortex as primary deposition sites within 30 min of administration.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Sermorelin for research and laboratory use. View UK stock →
Summary: Sermorelin in Neurological Research
Sermorelin engages CNS biology through two mechanistically distinct but complementary systems: direct hippocampal and cortical GHRHR signalling via cAMP-PKA-CREB-BDNF, producing neuroprotection, neurogenesis, LTP enhancement, dendritic spine density increases and cognitive improvements; and indirect IGF-1-mediated neurotrophic effects from elevated hepatic IGF-1 acting on neuronal IGF-1R to promote synaptic plasticity, anti-neuroinflammation and vascular biology. In aged animals, these mechanisms partially reverse somatopause-associated neurogenic decline, cognitive impairment, neuroinflammation and cerebrovascular insufficiency. In Alzheimer’s models, Sermorelin reduces amyloid burden, enhances clearance mechanisms and improves hippocampal-dependent memory. These comprehensive neurological findings position Sermorelin as a tool compound for investigating GH-axis restoration approaches to cognitive neuroscience and neurodegenerative disease research.
